ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1261

The Impact of Remission and Low Disease Activity Attainment on Health-related Quality of Life in Two Phase III Clinical Trials of Belimumab in Systemic Lupus Erythematosus
Abstract Number: 1351

The Impact of Skin Involvement and Depression on Patient Acceptable Symptom State in Patients with Psoriatic Arthritis and Psoriasis: Results from a Multinational Survey
Abstract Number: 0464

The Impact of Timely Post-Discharge Follow-up on Readmission Risk Among Patients with Systemic Lupus Erythematosus
Abstract Number: 1873

The Importance of Lower Extremity Vein Wall Thickness in Patients with Behcet’s Syndrome
Abstract Number: 0336

The Incremental Clinical Utility of a Multianalyte Assay Panel with Cell-Bound Complement Activation Products versus a Traditional ANA Testing Strategy for the Diagnosis and Treatment of SLE
Abstract Number: 0158

The Influence of Age on the Prevalence of Inflammatory and Post-inflammatory MRI Lesions in the Sacroiliac Joints of Patients with and Without Axial Spondyloarthritis
Abstract Number: 1663

The Influence of Comorbidity on Mortality in Patients with Rheumatoid Arthritis 1980-2015: A Longitudinal Population-based Study in Western Australia
Abstract Number: 1153

The Influence of Companions on a Patient’s Decision to Transition to a Biosimilar: A Randomized Controlled Trial
Abstract Number: 1186

The Kardashian Index of Rheumatology Program Directors: Comparing Scholarly Activity and Twitter Use of Rheumatology Fellowship Program Directors in the United States
Abstract Number: 0993

The Mechanistic Basis of anti-CD6 as a Novel Form for the Treatment of Autoimmune Diseases and Cancer
Abstract Number: 0025

The Modulatory Capacity of Galectin-3 on the Programmed Death-1 Signaling Axis in Rheumatoid Arthritis
Abstract Number: 1072

The Multidisciplinary Approach with Patient Collaboration Improve the Clinical Effectiveness of the Intervention
Abstract Number: 0036

The NAD+ Metabolism Is Altered in Rheumatoid Arthritis and Its Modulation with NAD+ Boosters Exhibits Key Anti-Inflammatory and Anti-Oxidant Effects
Abstract Number: 0571

The National Incidence of Clinically Diagnosed Psoriatic Arthritis in Sweden 2014-2016
Abstract Number: 1226

The Neuro-QOL Upper Extremity Function Scale: New Opportunities to More Reliably and Precisely Measure Self-reported Hand Function and Self-care Activities in People with RA

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].